Molina Healthcare, Inc. (NYSE: MOH) today announced that it had expanded
the size of its Board of Directors from 9 to 11 and elected Steven
James, Dale Wolf, and Daniel Cooperman as new independent non-executive
Molina Healthcare, Inc. (NYSE: MOH) today announced that it had expanded the size of its Board of Directors from 9 to 11 and elected Steven James, Dale Wolf, and Daniel Cooperman as new independent non-executive directors. “We are delighted to welcome Steve, Dale and Daniel to Molina’s Board of Directors,” said J. Mario Molina, M.D., president and chief executive officer of Molina Healthcare, Inc. “Our management team will benefit from the perspectives and experience of these accomplished new board members.” Steven James is a retired audit partner from Ernst & Young LLP with 30 years of experience providing accounting, auditing, and consulting services to health and managed care companies. James joined Ernst & Whinney (predecessor to Ernst & Young LLP) in 1979, was promoted to partner in 1992, became the leader of Ernst & Young’s Pacific Southwest Area Health Sciences practice in 2005, and retired from Ernst & Young LLP in 2009. James graduated with a Bachelor of Science degree in Business Administration with an emphasis in Accounting from the University of Redlands and is a certified public accountant. Dale Wolf has served as the Executive Chairman of Correctional Healthcare Companies, Inc., a national provider of correctional health care solutions, since 2002. From 2005 to 2009, Wolf served as chief executive officer of Coventry Health Care, Inc., a diversified national healthcare company, and served as the executive vice president, chief financial officer, and treasurer of Coventry Health Care, Inc. from 1996 to 2004. Wolf was also a member of the Board of Directors of Coventry Health Care, Inc. from 2005 to 2009, and a member of the Board of Directors of Catalyst Health Solutions, Inc. from 2003 to 2012. Wolf graduated magna cum laude from Eastern Nazarene College with a Bachelor of Arts degree in Mathematics and from the MIT Sloan School Senior Executive Program. He is also a fellow in the Society of Actuaries.